Zevra Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

• Zevra Therapeutics Inc ZVRA.OQ reported quarterly adjusted earnings of $1.21​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -48 cents. The mean expectation of eight analysts for the quarter was for earnings of $1.50 per share. Wall Street expected results to range from -12 cents to $2.64 per share.

• Revenue rose 481.7% to $25.88 million from a year ago; analysts expected $22.54 million.

• Zevra Therapeutics Inc's reported EPS for the quarter was $1.21​.

• The company reported quarterly net income of $74.71 million.

• Zevra Therapeutics Inc shares had risen by 32.8% this quarter and gained 40.3% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 87.2% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for Zevra Therapeutics Inc is $25.00, about 53.2% above its last closing price of $11.70

This summary was machine generated from LSEG data August 12 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)